Joint Financing Agreement with Sweden’s NXT2B may allow greater access to Cancer and Neurodegenerative Disease Diagnosis in Emerging and Developing Markets
ge healthcare
GE Healthcare Receives FDA Clearance of Q. Freeze, Helps Clinicians Assess Cancer Treatment ResponseQ.Freeze imaging technology virtually eliminates a patient’s respiratory motion within PET/CT imaging, potentially resulting in healthcare cost savings GE Healthcare’s Medical Diagnostics business (MDx) has recently released the results of a study discussing the possibility of lower iodine concentration in abdominal CT scans. The study indicated that techniques like ASiRTM and VeoTM, and other advanced CT reconstruction techniques, when combined with VisipaqueTM , the isosmolar contrast agent, result in improved contrast enhancement. This enhancement is better that that achieved with iomeprol when both substances are administered at the same dose and rate. Bay Ridge Medical Imaging (BRMI), a leading provider of medical imaging services in the Brooklyn community, became the first facility in the United States to acquire GE Healthcare’s Discovery MR750w 3.0T scanner. The new system offers medical images at high quality. It is also highly patient friendly modality, providing more comfort to patients than other traditional MRI systems. In a recent announcement, Microsoft and GE Healthcare mentioned that they will establish a new healthcare IT joint venture. The latter will be concentrating on providing interoperable platforms for better management of patients, especially those with chronic conditions. Anson Community Hospital, Wadesboro, NC, has recently improved its medical imaging capabilities with a new 16-slice Brightspeed CT system from GE Healthcare. The new system is replacing an older CT machine that has been used for nearly 9 years. GE has provided the FDA with the device description and non-clinical information, including phantom testing, and detector performance evaluation Waukesha, WI – October 13, 2011– GE Healthcare, a unit of General Electric Company (NYSE:GE), announced today FDA 510(k) clearance of an innovative technology to aid the physician in breast cancer diagnosis. GE estimates that by 2020, more than 1 million women worldwide will be examined using SenoBright*, and this technology can help lead to more productive diagnosis paths for nearly 250,000 women. Radiologists around the world are experiencing the proven benefits of IDI Mammography Workflow Solution in their efforts to help ensure diagnostic confidence, maintain throughput and provide the best possible patient care. GE Healthcare recently reached the milestone of installing the 1,000th IDI MammoWorkstation worldwide to a private radiology practice in the east of France. |